Vistagen Therapeutics's quarterly market cap
declined
from Sep. 2025 ($138.06 Mil) to Dec. 2025 ($26.22 Mil) and
declined
from Dec. 2025 ($26.22 Mil) to Mar. 2026 ($22.64 Mil).
Vistagen Therapeutics's annual market cap
declined
from Mar. 2024 ($142.69 Mil) to Mar. 2025 ($72.49 Mil) and
declined
from Mar. 2025 ($72.49 Mil) to Mar. 2026 ($22.64 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Vistagen Therapeutics's Enterprise Value for Today is $-16.98 Mil.
Vistagen Therapeutics (NAS:VTGN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vistagen Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistagen Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vistagen Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Vistagen Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Vistagen Therapeutics's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vistagen Therapeutics (VTGN) has a Market Cap of $27.38 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Vistagen Therapeutics and its competitors. According to the industry distribution chart, Vistagen Therapeutics ranks #1042 out of 1431 companies in the Biotechnology industry, placing it in the top 72.8%.
Is Vistagen Therapeutics' Market Cap too high?
Vistagen Therapeutics' current Market Cap is $27.38 Mil. The Biotechnology industry median Market Cap is 117.63. Vistagen Therapeutics' value of $27.38 Mil is 76.7% below this industry median. Based on the distribution chart, Vistagen Therapeutics ranks #1042 out of 1431 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vistagen Therapeutics has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vistagen Therapeutics' Market Cap compare to PLUR and PTN?
According to the Biotechnology industry distribution chart, Vistagen Therapeutics ranks #1042 out of 1431 companies for Market Cap. This places Vistagen Therapeutics in the lower half of its industry. The industry median Market Cap is 117.63. Vistagen Therapeutics' value of $27.38 Mil is 76.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.63, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vistagen Therapeutics's current Market Cap of $27.38 Mil is 76.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Vistagen Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 117.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistagen Therapeutics's current Market Cap is $27.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistagen Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Vistagen Therapeutics (VTGN) is currently considered Possible Value Trap. The stock's GF Value™ is $2.20, compared to a current price of $0.67 — trading 69.7% below its estimated fair value. The current Market Cap is $27.38 Mil and 76.7% below the Biotechnology industry median of 117.63. Vistagen Therapeutics' overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Vistagen Therapeutics (VTGN), the current Market Cap is $27.38 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistagen Therapeutics (VTGN) Overvalued in 2026?
Based on GuruFocus' analysis, Vistagen Therapeutics stock appears to be undervalued.
The current stock price of $0.67 is trading 69.7% below its estimated GF Value™ of $2.20.
GuruFocus considers Vistagen Therapeutics to be Possible Value Trap.
Key valuation signals for VTGN:
Market Cap: $27.38 Mil
GF Value™: $2.20 vs. price of $0.67 (69.7% below fair value)
Industry Position: 76.7% below the Biotechnology median (#1042 of 1431)
No single metric tells the full story. See the VTGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
40GF Score
Get the complete analysis for VTGN
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VTGN has been successfully added to your 
